|Day Low/High||531.33 / 545.37|
|52 Wk Low/High||328.12 / 664.64|
Neither candidate seems to be the enemy of the market -- at least not yet.
I would not view what appears to be an increasingly likely Democratic victory as a reason to sell stocks.
* The 2016 Presidential election provided the contrary - a Trump win and an advancing stock market * The 2020 Presidential election may provide another contrary - a Biden win and an advancing market * President Trump's path to victory is narrowing *...
Markets now look to Treasury Secretary Mnuchin and Speaker Pelosi to do something.
"Just one more thing." -- Lt. Columbo The positive Regeneron antibody cocktail news underscores something that I planned to discuss in my opener tomorrow (Is This The Biden Bump?) Specifically, the market has already completed a consolidation phase ...
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Do these shares get back to the 2020 highs that were reached back in January?
Should the economy see some organic growth, this stock can run as high as $220.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
Wendy's, Regeneron and Teladoc -- why would you unload them now?
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Ask yourself: Would you pay a higher multiple for the company that puts together a successful cocktail for Covid-19?
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Markets are clearly different now. I did not grow up, nor was I trained for this environment. Nobody else you hear today was either.
I would wait until the next down day, and there will be one.
Now that REGN has clearly broken out above the highs of 2015 there is no chart resistance.
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
This list is not a buy list but a list of stocks that have been brought to new heights.
That's the really good news about why we could bounce back so quickly from Thursday's debacle.
The massive tock market drop was to be expected, and seasoned traders were prepared for it. But there was also some good news on the coronavirus vaccine/treatment front.
We're cheering what may be an aberration, a bullish employment number. We'll take what it brings - a wholesale shift in what we're buying and what we're selling to fund it.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.